vimarsana.com

Latest Breaking News On - Shawn iadonato - Page 8 : vimarsana.com

Kineta Announces FDA Acceptance of Investigational New Drug

SEATTLE, Nov. 15, 2022 (GLOBE NEWSWIRE) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing.

United-states
John-mullaly
Jacques-bouchy
Shawn-iadonato
Linkedin
Lifesci-advisors
Business-development-corporate-communications
Kineta-inc
Drug-administration
Exchange-commission
Yumanity-therapeutics-inc
Facebook

Kineta Appoints Keith Baker as Chief Financial Officer

/PRNewswire/ Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in.

Keith-baker
Shawn-iadonato
Genetics-corporation
Linkedin
Deloitte-touche
Element-data-inc
Exchange-commission
Armata-pharmaceuticals
Yumanity-therapeutics-inc
Facebook
Prnewswire-kineta-inc
Chief-financial-officer

vimarsana © 2020. All Rights Reserved.